enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Bayer says 2024 sales of prostate cancer drug above $1 billion

   www.aol.com/news/bayer-says-2024-sales-prostate...

   Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising ...

3. Eddie Jordan reveals ‘aggressive’ cancer diagnosis in health ...

   www.aol.com/news/eddie-jordan-reveals-aggressive...

   Following the conclusion of the 2024 F1 ... April, I was diagnosed with bladder and prostate cancer, and then it spread into the spine and the pelvis, so it was quite aggressive,” Jordan told co ...

4. King Charles’ Cancer Treatment Will Continue into the New ...

   www.aol.com/king-charles-cancer-treatment...

   King Charles at an event at his country home, Highgrove House, on Dec. 13, 2024 King Charles ’ cancer treatment will continue into the New Year, but it is moving “in a very positive direction ...

5. Prostvac - Wikipedia

   en.wikipedia.org/wiki/Prostvac

   PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]

6. Pfizer (PFE) Q3 2024 Earnings Call Transcript - AOL

   www.aol.com/pfizer-pfe-q3-2024-earnings...

   The TALAPRO-2 results show how we continue innovating to improve survival for men with prostate cancer, which is the second most common cancer in men and the fifth most common cause of cancer ...

7. Prostate cancer screening - Wikipedia

   en.wikipedia.org/wiki/Prostate_cancer_screening

   Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.